

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Shanghai Bio-heart Biological Technology Co., Ltd.**

### **上海百心安生物技術股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2185)**

## **PROPOSED CHANGE OF DIRECTOR CHANGE OF COMPOSITION OF REMUNERATION COMMITTEE PROPOSED CHANGE OF SUPERVISOR AND CLOSURE OF REGISTER OF MEMBERS OF H SHARES FOR EXTRAORDINARY GENERAL MEETING**

The board of directors (the “**Board**”) of Shanghai Bio-heart Biological Technology Co., Ltd. (the “**Company**”) hereby announces that:

### **PROPOSED CHANGE OF DIRECTOR**

On September 26, 2022, Ms. Li Cai (蔡俐) (“**Ms. Cai**”) proposes to resign as a non-executive director and a member of the Board’s remuneration committee (the “**Remuneration Committee**”), with effect from the date on which the proposed appointment of the new director is approved by the shareholders of the Company (the “**Shareholders**”) at the first extraordinary general meeting for 2022 (the “**EGM**”) of the Company, to be held on Thursday, November 10, 2022. Ms. Cai resigned from her position due to her other personal commitments. Ms. Cai has confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of the Shareholders or The Stock Exchange of Hong Kong Limited.

The Board would like to express its heartfelt gratitude to Ms. Cai for her valuable contributions to the Company during her tenure as a non-executive director.

Ms. Peili Wang (“**Ms. Wang**”) has been nominated as an executive director. Such appointment is subject to the approval by the Shareholders at the EGM. The term of Ms. Wang will commence on the date of approval by the Shareholders at the EGM and end at the expiry of the current session of the Board.

Details of Ms. Wang, which are required to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), are set out as follows:

**Ms. Peili Wang (王佩麗)**, aged 38, was appointed as a supervisor of the Company on October 25, 2018. As a supervisor, Ms. Wang was primarily responsible for the supervision of the performance of the directors and senior management members. Ms. Wang has also been the financial manager of the Company since July 1, 2014 and the financial manager of Shanghai AngioCare Medical Technology Co. Ltd.\* (上海安通醫療科技有限公司) since September 2011. Ms. Wang has over 10 years of experience in financial management. From September 2004 to June 2005, she was an accountant at the Korman Shipping Company Limited (上海和明航運服務有限公司). From July 2005 to May 2006, she was an accountant at the Shanghai Heming International Freight Company Limited (和明國際貨運有限公司). From June 2006 to July 2010, she was the financial manager of Shanghai Xiyuan International Trading Company (上海曦原國際貿易有限公司). From August 2010 to December 2013, she was the financial manager of Forerunner Medical (Shanghai) Company Limited (方潤醫療器械科技(上海)有限公司).

Ms. Wang obtained her part-time bachelor’s degree in accountancy from the Shanghai University of Finance and Economic (上海財經大學) in January 2009. She was admitted as Certified Public Accountant in China in May 2010.

Save as disclosed above, as at the date of this announcement, Ms. Wang does not hold and has not held any directorships in any other listed companies or any other position of the Company and its subsidiaries in the past three years.

Ms. Wang has no relationship with any directors, supervisors, senior management, substantial shareholders (as defined in the Listing Rules) or controlling shareholders (as defined in the Listing Rules) of the Company, nor does she have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Subject to the approval by the Shareholders of Ms. Wang’s appointment as an executive director, Ms. Wang will enter into a service contract with the Company for a term commencing from the date of her appointment and ending on the expiration of the term of the current session of the Board. Pursuant to the articles of association of the Company, Ms. Wang will be subject to re-election upon the expiry of her term of office. Ms. Wang will not receive remuneration as executive director from the Company.

Save as disclosed above, as far as the Board is aware, there are no any other matters in relation to the proposed appointment of Ms. Wang as a director of the Company that need to be brought to the attention of the Shareholders nor any information that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

## **CHANGE OF COMPOSITION OF REMUNERATION COMMITTEE**

Following Ms. Cai’s resignation, Mr. George Chien Cheng Lin, an independent non-executive director of the Company, will be appointed as a member of the Remuneration Committee, with effect from the date on which relevant change of director is approved by the Shareholders at the EGM.

## PROPOSED CHANGE OF SUPERVISOR

Due to her proposed appointment as an executive director on September 26, 2022, Ms. Wang has tendered her resignation as a supervisor of the Company, with effect from the date on which the proposed appointment of the new supervisor is approved by the Shareholders of the Company at the EGM. Ms. Wang has confirmed that she has no disagreement with the board of supervisors of the Company during her term of office and there is no other matter relating to her resignation that needs to be brought to the attention of the Shareholders.

The Company would like to express its heartfelt gratitude to Ms. Wang for her valuable contribution to the Company during her term of office as a supervisor of the Company.

Mr. Lei Zhu (“**Mr. Zhu**”) has been nominated as a supervisor. Such appointment is subject to the approval by the Shareholders at the EGM. The term of Mr. Zhu will commence on the date of approval by the Shareholders at the EGM and end at the expiry of the current session of the board of supervisors of the Company.

Details of Mr. Zhu, which are required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules are set out as follows:

**Mr. Lei Zhu (朱磊)**, aged 35, has been our quality compliance director since September 2020. He is also a limited partner of Shanghai Baixinantong Enterprise Management Consulting L.P. (Limited Partnership) (上海百心安通企業管理諮詢合夥企業(有限合夥)), holding 1.5% of its equity interest.

Mr. Zhu has over 10 years of experience in the medical industry. From August 2009 to September 2020, he served as the manager of quality and regulation at Shanghai Microport Medical (Group) Co., Ltd (上海微創醫療器械(集團)有限公司). In his role as the manager of quality and regulation, he supervised the quality management work in the storage, maintenance and transport of medical devices, the collection of quality management information, and led the training of quality management for employees.

Mr. Zhu obtained his bachelor’s degree in engineering from Nanjing Technology University (南京工業大學) in June 2009. He then obtained his bachelor’s degree in law from Xi’an Political College (西安政治學院) in December 2013. He obtained his master’s degree in engineering from Tongji University (同濟大學) in December 2019. In June 2014, Mr. Zhu became a qualified national intermediate engineer holds General Administration of Quality Supervision, Inspection and Quarantine of the People’s Republic of China.

Save as disclosed above, as at the date of this announcement, Mr. Zhu does not hold and has not held any directorships in any other listed companies or any other position of the Company and its subsidiaries in the past three years.

Mr. Zhu has no relationship with any directors, supervisors, senior management, substantial shareholders (as defined in the Listing Rules) or controlling shareholders (as defined in the Listing Rules) of the Company, nor does she have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Subject to the approval by the Shareholders of Mr. Zhu's appointment as a supervisor, Mr. Zhu will enter into a service contract with the Company for a term commencing from the date of his appointment and ending on the expiration of the term of the current session of the board of supervisors. Pursuant to the articles of association of the Company, Mr. Zhu will be subject to re-election upon the expiry of his term of office. Mr. Zhu will not receive remuneration as supervisor from the Company.

Save as disclosed above, as far as the Board is aware, there is no any other matters in relation to the proposed appointment of Mr. Zhu as a supervisor of the Company that need to be brought to the attention of the shareholders of the Company nor any information that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

## **CLOSURE OF REGISTER OF MEMBERS**

For the purpose of determining the entitlement of holders of H shares to attend and vote at the EGM, the register of members of H shares of the Company will be closed from Tuesday, October 11, 2022 to Thursday, November 10, 2022, both days inclusive, during which no transfer of H shares will be registered.

To be eligible to attend and vote at the EGM, all properly completed transfer documents, accompanied by relevant share certificate, must be lodged with the Company's H Share registrar, Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong no later than 4:30 p.m. on Monday, October 10, 2022 for registration.

A circular containing, inter alia, details of the proposed appointment of Ms. Wang and Mr. Zhu, together with a notice of the EGM, will be dispatched to the Shareholders as soon as practicable.

By Order of the Board  
**Shanghai Bio-heart Biological Technology Co., Ltd.**  
**Philip Li WANG**  
*Chairman and executive director*

Shanghai, the People's Republic of China, September 26, 2022

*As at the date of this announcement, the Board of the Company comprises Mr. Philip Li WANG as chairman and executive director, Mr. Yunqing WANG as executive director, Ms. Li CAI, Mr. Quan ZHOU and Mr. Ji CHEN as non-executive directors, and Mr. Charles Sheung Wai CHAN, Mr. Xubo LU and Mr. George Chien Cheng LIN as independent non-executive directors.*

\* *For identification purpose only*